Squarepoint
VIR icon

Squarepoint’s Vir Biotechnology VIR Stock Holding History

Squarepoint’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.29M Buy
126,141
+100,128
+385% +$953K ﹤0.01% 2706
2026
Q1 		$233K Buy
26,013
+5,146
+25% +$41K ﹤0.01% 3875
2025
Q4 		$126K Sell
20,867
-256,448
-92% -$1.53M ﹤0.01% 3995
2025
Q3 		$1.58M Buy
277,315
+169,955
+158% +$869K ﹤0.01% 2291
2025
Q2 		$541K Buy
107,360
+53,662
+100% +$288K ﹤0.01% 3201
2025
Q1 		$348K Sell
53,698
-160,565
-75% -$1.43M ﹤0.01% 3621
2024
Q4 		$1.57M Buy
214,263
+110,563
+107% +$872K ﹤0.01% 2632
2024
Q3 		$777K Buy
103,700
+50,290
+94% +$437K ﹤0.01% 2796
2024
Q2 		$475K Buy
+53,410
New +$512K ﹤0.01% 3118
2024
Q1 		– Sell
-221,855
Closed -$2.23M – 4650
2023
Q4 		$2.23M Buy
221,855
+49,214
+29% +$450K ﹤0.01% 1920
2023
Q3 		$1.62M Buy
+172,641
New +$2.46M ﹤0.01% 1979
2022
Q3 		– Sell
-70,630
Closed -$1.8M – 3479
2022
Q2 		$1.8M Sell
70,630
-48,578
-41% -$1.13M 0.01% 1261
2022
Q1 		$3.07M Buy
119,208
+95,737
+408% +$2.84M 0.01% 918
2021
Q4 		$983K Buy
+23,471
New +$920K ﹤0.01% 1708
2021
Q2 		– Sell
-16,178
Closed -$829K – 3730
2021
Q1 		$829K Buy
+16,178
New +$872K ﹤0.01% 1655
2020
Q1 		– Sell
-13,234
Closed -$166K – 2557
2019
Q4 		$166K Buy
+13,234
New +$177K ﹤0.01% 2263

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Squarepoint's VIR Position: Q2 2026 in Review

Squarepoint increased its Vir Biotechnology (VIR) stake by 385% in Q2 2026, buying an estimated $953K and bringing the position to 126,141 shares worth $1.29M. The position accounts for ﹤0.01% of the portfolio, ranked #2706.

Squarepoint first reported a position in VIR in Q4 2019 and has held it in 16 quarters since. The position peaked at $3.07M in Q1 2022. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Squarepoint held 126,141 shares of Vir Biotechnology worth $1.29M as of Q2 2026.
  • Squarepoint bought 100,128 Vir Biotechnology shares in Q2 2026, an estimated $953K.
  • Vir Biotechnology made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #2706 holding.
  • Squarepoint first reported a position in Vir Biotechnology in Q4 2019 and has held it in 16 quarters since.
  • Squarepoint's Vir Biotechnology position peaked at $3.07M in Q1 2022.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.